Oncology
ICON's fastest-growing therapeutic area and testament to our success in conducting oncology clinical trials.
Oncology
Oncology is currently ICON's fastest-growing therapeutic area and a testament to our success in conducting oncology clinical trials. To date, ICON has conducted over 870 oncology studies, assessing over 143,000 patients at nearly 24,000 sites worldwide.
ICON’s Oncology Solution expedites every aspect of a cancer drug trial. It combines global experience in all Phases of oncology drug development with expertise in tumor imaging, laboratory (including PK/PD and Biomarkers) IVRS, central data management , electronic data capture and regulatory oncology issues.
Our clinical trial experience includes the following oncology indications:
|
Oncology Therapeutic Area Group (TAG)
The in-depth therapeutic knowledge of ICON’s Oncology TAG spans the entire drug development process. Senior members of this group have extensive hematology and oncology drug development experience and have worked on a wide variety of oncology programs and drug classes, including:
|
|
The scope of responsibilities for ICON’s Oncology TAG members includes:
|
|
Investigative Sites
Our global investigator database includes thousands of oncology investigative sites worldwide. As such, ICON has close working relationships and consulting agreements with physicians at most of the major tertiary and academic cancer treatment centers as well as cooperative groups and consortiums. These extensive and well-established relationships provide ICON with the ability to obtain information quickly and concisely regarding development issues in oncology and effective recruitment strategies.